Regulatory Services Department at Taj Pharma:

Dossier & Regulatory Support

At Taj Pharma, our Regulatory Services Department stands as a cornerstone of global pharmaceutical compliance. Our comprehensive capabilities in dossier compilation, clinical studies, analytical validation, pharmacovigilance, and documentation legalization cater to the diverse regulatory demands of ASEAN, CIS, GCC, Africa, and other ROW markets. With unmatched proficiency in both regional and international standards, we ensure seamless, audit-ready submissions, safeguarding product approvals and enhancing market access worldwide.


Comprehensive Dossier Compilation: CTD, ACTD & Country-Specific Modules

Taj Pharma is equipped to compile regulatory dossiers in CTD (Common Technical Document), ACTD (ASEAN Common Technical Dossier), and custom formats as per specific regulatory requirements. Our services cover:

  • Module-wise dossier preparation (Modules 1 to 5)
  • Country-specific formatting and regulatory language compliance
  • Region-focused compilation for ASEAN, CIS, GCC, Africa, LATAM, and other international agencies

We maintain structured, technically complete, and submission-ready documentation that meets the standards of agencies such as WHO, FDA, EMA, TGA, SFDA, ANVISA, and more.

Comprehensive Dossier Compilation: CTD, ACTD & Country-Specific Modules

At Taj Pharma’s state-of-the-art Oral Solid Dosage (OSD) manufacturing facility, regulatory dossier compilation is an integrated core competency embedded within the product development lifecycle. Our Regulatory Affairs Department operates in synchronization with R&D, QA/QC, F&D, production, and analytical divisions to generate technically sound, compliant, and submission-ready dossiers for global registrations.

We specialize in preparing Common Technical Document (CTD), ASEAN Common Technical Dossier (ACTD), and country-specific dossier formats, customized to meet the individual requirements of health authorities across ASEAN, CIS, GCC, Africa, LATAM, and various ROW markets.


End-to-End Module-wise Dossier Preparation (Modules 1–5)

Module 1 – Regional Administrative and Product Information

  • Country-specific templates and administrative documents (Application forms, Product Information, Prescribing Information, PILs, and Labeling Artwork) are compiled in strict adherence to regulatory agency guidelines.
  • Inclusion of region-specific declarations, GMP certificates (WHO GMP/PICs), legalized documents, FSC/CPP, and QP declarations.
  • Adaptation of Module 1 per agency: e.g., eCTD baseline submissions for GCC (Saudi FDA), PDF format for TGA, or paper dossiers for francophone African agencies.

Module 2 – Overviews and Summaries

  • Preparation of high-level Quality Overall Summary (QOS), Non-clinical overview, and Clinical overview in ICH-compliant formats.
  • Integration of P.2 Pharmaceutical Development, justifications for choice of excipients, formulation development studies, and comparability protocols.
  • Regulatory strategy and bridging justification for waivers, when applicable, supported by Biowaiver rationale for BCS Class I/III drugs.

Module 3 – Quality (CMC)

  • Highly detailed Module 3.2.S (Drug Substance) and 3.2.P (Drug Product) incorporating:
    • API specifications, source documentation, route of synthesis, control of critical process parameters, impurity profiling, and stability data aligned with ICH Q3A/B/C.
    • For FDF: Finished product specs, manufacturing process validation (3.2.P.3.3), container closure system compatibility studies, and stability studies under Zone IVb (30°C/75%RH) conditions for tropical markets.
  • Granular batch manufacturing records (BMRs) and batch analysis reports for pivotal batches used in BE studies or process validation are appended for traceability.

Module 4 – Non-clinical Study Reports

  • In generic applications, literature references, toxicological justification of excipients, and impurity qualification are presented based on published toxicology databases (TOXNET, ToxCast) and ICH M7 risk assessment.

Module 5 – Clinical Study Reports

  • Integration of BA/BE summary reports, clinical protocols, ethics committee approvals, CRO accreditation, raw data sets, and ANOVA-based statistical treatment of pharmacokinetic data for solid oral formulations (IR and MR).
  • For FDCs or high-barrier generics, clinical study rationales and references to innovator comparator profiles are presented using a comparative dissolution profile (CDP) backed by HPLC chromatograms.

Customized Country-Specific Formatting and Regulatory Compliance

  • Documents are tailored to local regulatory nomenclature, document sequencing, and language translation (e.g., Russian, French, Arabic) as per local health authority expectations.
  • Dossier submissions for Uzbekistan, Kazakhstan, and Belarus comply with EAEU harmonized structure, while submissions to Saudi FDA, UAE MOH, and Oman MOH are compiled in eCTD format with XML backbone validation.
  • For South Africa’s SAHPRA, dossiers are structured with ZA CTD guidance including PIF (Product Information File) and Site Master File.
  • All country-specific pharmacopoeial compliance (USP/BP/Ph.Eur/Ph.Int) and ICH Q1-Q12 references are meticulously mapped and cross-referenced.

Regulatory Intelligence & Lifecycle Support

Taj Pharma’s OSD regulatory team engages in continuous regulatory intelligence and gap analysis to support:

  • Initial product registration
  • Post-approval changes (variation filings)
  • Renewals and license maintenance
  • Reformatting old dossiers into CTD/eCTD structure

We maintain strict adherence to agency submission checklists (e.g., ANVISA’s RDC 73/2016, GCC-DR guideline 2017) and ensure each submission is validated with digital tools like Lorenz docuBridge, eValidator, and Extedo.


Global Filing Experience & Agency Readiness

Taj Pharma OSD plant has a proven dossier filing track record in the following territories:

  • ASEAN: Philippines (FDA), Malaysia (NPRA), Vietnam (DAV), Indonesia (BPOM)
  • CIS: Russia (Minzdrav), Kazakhstan, Uzbekistan
  • GCC: Saudi Arabia (SFDA), UAE (MOHAP), Oman, Bahrain
  • Africa: Nigeria (NAFDAC), Ghana (FDA), Kenya (PPB), Ivory Coast (DPM)
  • ROW Markets: Sri Lanka, Myanmar, Yemen, Cambodia, Peru, Bolivia

Our submissions meet GMP site accreditation requirements and align with ICH M4, M8, and regional CTD granularity levels.


Commitment to Regulatory Excellence

By leveraging regulatory foresight, structured documentation processes, and cross-functional coordination, Taj Pharma’s Regulatory Services ensures:

  • Right-first-time dossier submissions
  • High approval rates with minimal deficiency queries
  • Efficient product launch timelines

All documentation is backed by document control SOPs, change control protocols, validation master plans, and QA oversight, making our OSD plant a regulatory-compliant, export-ready hub for global markets.


eCTD/ACTD/CTD Dossier Submission Expertise

We specialize in:

  • Electronic CTD (eCTD) submissions through validated software solutions
  • Region-specific eCTD lifecycle management and sequence tracking
  • ACTD/CTD document conversion for regulatory agencies transitioning to digital formats

Each file is carefully validated and hyperlinked to enhance review timelines and acceptance rates across multiple regulatory platforms.

eCTD/ACTD/CTD Dossier Submission Expertise

At Taj Pharma’s Oral Solid Dosage (OSD) Plant, our Regulatory Affairs division is strategically equipped with the latest tools and regulatory infrastructure to manage complex dossier submissions across multiple global regulatory jurisdictions. With a focus on electronic Common Technical Document (eCTD), ASEAN CTD (ACTD), and ICH CTD formats, we support seamless global product registrations while adhering to evolving digital regulatory landscapes.

Our team works within a fully digitized, validated, and compliance-driven environment, ensuring that every submission meets the highest technical standards required by agencies such as US FDA, EMA, Health Canada, SFDA (Saudi Arabia), SAHPRA, TGA, WHO, ANVISA, and other regional authorities.


1. eCTD Submission Capabilities Using Validated Regulatory Publishing Tools

Taj Pharma utilizes 21 CFR Part 11-compliant publishing platforms like Extedo eCTDmanager, Lorenz docuBridge, MasterControl, and Veeva Vault RIM to generate technically valid eCTD submissions.

Key technical proficiencies include:

  • XML backbone creation & validation: Complete metadata tagging, folder-level indexing, and lifecycle granularity with seamless integration of UUIDs, hyperlinks, and bookmarks.
  • Granularity compliance: Following agency-specific granularity requirements (e.g., US FDA granularity differs from EMA or GCC eCTD specifications).
  • eValidator usage: Agency-specific validation checks using tools like FDA eCTD Validator, EMA EU Gateway WebTrader Validator, and Saudi SFDA eCTD Validation Tool.
  • PDF publishing standards: Adherence to PDF v1.4–1.7, with optimized fonts, non-scanned searchable content, active Table of Contents (TOC), and embedded bookmarks.

We ensure the complete publishing cycle is supported from baseline submission to subsequent lifecycle operations, including amendments, variations, renewals, and withdrawals using appropriate submission types and sequence numbers (0000, 0001, etc.).


2. Region-Specific eCTD Lifecycle Management & Sequence Tracking

Our regulatory systems allow us to track submission history, manage sequence numbers, and maintain traceability across the entire product lifecycle, tailored to individual regional authorities:

  • US FDA (CDER & CBER): Usage of ESG (Electronic Submission Gateway) with valid IND, ANDA, or NDA tracking IDs, eCTD submissions through WebTrader interface.
  • EMA (EU Module 1): Submissions via EU Gateway and EU Submission Portal, following EMA’s VNeeS and eCTD specifications, including xEVMPD compliance.
  • GCC (Saudi FDA, UAE MOH): Submissions follow the GCC-DR eCTD specifications, with validations using GCC Validator, XML checksum integrity, and hyperlink review readiness.
  • Health Canada: Dossier lifecycle follows RPS (Regulatory Project Submission) Model, enabling Module 1 country-specific formatting.
  • South Africa (SAHPRA): Implementation of eCTD under ZA CTD format, with recent transition toward electronic-only submissions using ZA-1.0 eCTD granularity.

Each lifecycle operation (e.g., supplemental data, response to deficiency, clinical update) is submitted with its corresponding sequence ID, submission type, submission description, and metadata in the regional format.


3. ACTD/CTD Document Conversion for Markets Transitioning to eCTD

For regulatory authorities that are shifting from traditional paper-based or ACTD formats to eCTD (e.g., Indonesia, Vietnam, Jordan, Uzbekistan, Nigeria), our team performs document re-architecture and conversion:

  • ACTD to CTD Mapping: Reorganizing document structure from four-part ASEAN format to ICH CTD five-module format, while ensuring content integrity and harmonization.
  • Scanned file digitization: Optical Character Recognition (OCR) for non-editable PDFs and replacing legacy scanned content with text-searchable, hyperlink-enabled PDFs.
  • Metadata enrichment: Assigning correct document properties (Module number, Document ID, TOC entry, keywords) to enable navigation in agency viewing tools.
  • Language translation & localization: Ensuring labeling, SmPC, PIL, and regional forms are translated and formatted to meet language compliance (Arabic, French, Russian, Vietnamese).

This ensures smooth submission readiness even for regulatory environments lacking full eCTD capability, while maintaining ICH M4Q, M4S, and M4E standards.


4. Technical File Validation, Hyperlinking & Document Readability

A critical step in Taj Pharma’s submission workflow includes meticulous document-level validation before final publishing. Our QA-reviewed publishing process ensures:

  • Hyperlink integrity: Cross-referencing of certificates, method validations, clinical appendices, and SmPC references within and across modules.
  • Validation checklists: Review against agency technical validation criteria (e.g., EMA’s EU eCTD CESP criteria, GCC DR checklist, US FDA’s technical rejection criteria).
  • Document readability enhancements: Consistent page numbering, legible fonts (Arial 11 or Times New Roman 12), embedded bookmarks, active headers/footers, and color-coded response tracking in deficiency replies.
  • Node extension management: Correct application of “leaf titles” and “node extensions” for sub-documents like Stability Protocols, Validation Protocols, and Analytical Test Methods.

Each dossier undergoes a Regulatory Submission Readiness Review (RSRR) before final sequence generation and delivery via appropriate channels (e.g., FTP, CD/DVD, ESG, EU portal, or physical drive).


Regulatory Submission Case Studies from Taj Pharma OSD Plant

  • Saudi Arabia (SFDA): Successful eCTD submission for 3 OSD formulations with complete Module 1 customization, validated XML metadata, and 100% hyperlink compliance, resulting in zero-cycle deficiency approval.
  • Russia (Minzdrav): ACTD-to-eCTD dossier reformatting for 7 products with Russian-translated Module 1 and lifecycle management for 2 post-approval variations.
  • Philippines FDA: Hybrid submission strategy combining CTD Module 2–5 in digital format, Module 1 in ACTD country-specific forms, and integration of WHO GMP site certifications.
  • Nigeria (NAFDAC): Dossier conversion from non-CTD to CTD format, including hyperlinked comparative dissolution reports, BA/BE summary tables, and region-specific SmPC/PIL localization.

Digital Regulatory Excellence at Taj Pharma

Taj Pharma’s OSD plant has institutionalized regulatory digitization, embedding it within every stage of product lifecycle management—from development to post-marketing support. Our commitment to eCTD publishing quality, document control, metadata accuracy, and agency-specific granularity ensures accelerated submission timelines, reduced deficiencies, and enhanced product launch capability across global markets.

Our cross-functional regulatory publishing team works in tandem with formulation, analytical, and clinical divisions to ensure dossiers are data-driven, audit-ready, and globally aligned.


DMF (Drug Master File) – Open & Closed Part Preparation

Our team supports clients in requesting and maintaining comprehensive Drug Master Files (DMF), ensuring robust documentation for API used at our plant:

  • Open Part (for customer reference)
  • Closed Part (confidential manufacturing details)
  • Compliant with US-DMF (Type II), EU-ASMF, CEP, and Canadian DMFs
  • Secure handling of proprietary data with full lifecycle support

We ensure that all technical data, manufacturing processes, impurity profiles, and analytical methods are meticulously documented.

Drug Master File (DMF) – Open & Closed Part Management at Taj Pharma OSD Plant

At Taj Pharma’s Oral Solid Dosage (OSD) manufacturing plant, we maintain a regulatory-driven and technically robust framework for sourcing, compiling, and managing Drug Master Files (DMFs) for all active pharmaceutical ingredients (APIs) used in our finished dosage formulations. Our DMF system ensures full traceability, regulatory transparency, and compliance with international regulatory authorities including US FDA (Type II DMF), EU ASMF, Health Canada, and EDQM CEP submissions.

In alignment with ICH Q7, Q11, and WHO TRS 986 Annex 2, Taj Pharma’s regulatory and procurement teams jointly ensure that every API vendor is qualified, audited, and compliant, and that DMF documentation is complete and current, both from the technical and regulatory perspectives.


Comprehensive Collection of Open & Closed Parts from Qualified API Vendors

Taj Pharma mandates the submission of complete Open and Closed Parts of DMFs from all API suppliers prior to technical onboarding and commercial engagement.

Open Part (Applicant’s Part) – Collected from All API Vendors

  • Provided by the API manufacturer and shared with Taj Pharma and regulatory authorities (as applicable).
  • Includes non-confidential technical data required by the applicant (Taj Pharma) for inclusion in Module 3.2.S of the CTD dossier:
    • General information (nomenclature, structure, general properties)
    • Manufacturer’s address, manufacturing sites, and GMP certification
    • Specification of API (Ph. Eur/USP/BP or in-house specs)
    • Analytical validation reports
    • Stability summary and data
    • Packaging, container closure, and retest period information
    • Control of critical intermediates and process reagents

Closed Part (Restricted Part) – Confidential to API Manufacturer

  • Contains proprietary manufacturing process information and internal controls which are only submitted directly to regulatory agencies by the API vendor.
  • Includes:
    • Detailed route of synthesis including all intermediates
    • Process flow diagrams and batch process descriptions
    • In-process controls and critical quality attributes (CQAs)
    • Identification and control of potential impurities including genotoxic and nitrosamine impurities
    • Process validation and reprocessing strategies
    • Impurity fate and purge studies
    • TSE/BSE certification (where applicable)

Taj Pharma maintains strict confidentiality and data protection practices under quality agreements and confidentiality disclosure agreements (CDAs) with API suppliers to ensure that sensitive process knowledge remains protected, even as we facilitate submissions or cross-referencing with regulatory bodies.


Global DMF Formats & Compliance

Our regulatory affairs team ensures that all collected DMFs comply with the specific requirements of target markets:

  • US FDA – Type II DMF: Lifecycle maintenance with Letter of Authorization (LOA), annual updates, and access via ESG (Electronic Submission Gateway).
  • EU-ASMF (Active Substance Master File): Coordination with EU-based agents for compilation and submission of Applicant and Restricted parts, including QOS.
  • Canadian DMF: Alignment with Health Canada’s Guidance for Industry, including specifications on impurity control and elemental impurity compliance (ICH Q3D).
  • EDQM CEP (Certificate of Suitability): Ensures Ph. Eur. monograph compliance; supports accelerated approval for Europe, Middle East, and Africa.
  • Japan DMF (J-DMF): Vendor partnerships for JP compliance where applicable.

Vendor Qualification & Auditing Process

Only approved API vendors with GMP-compliant manufacturing facilities and acceptable DMFs are considered by Taj Pharma. Our process includes:

  1. Vendor Questionnaire & Quality Technical Agreement (QTA)
  2. Audit of manufacturing site (on-site or remote, as per risk level)
  3. Review of DMF for completeness and regulatory compliance
  4. Verification of impurity data including residual solvents, heavy metals (ICH Q3D), and genotoxins
  5. NDMA/NDEA impurity risk assessment and control plan

All documents are reviewed and archived in Taj Pharma’s Regulatory Dossier Management System, integrated with our Enterprise Resource Planning (ERP) and Document Control Systems (DCS).


Nitrosamine Impurity Control: NDMA & NDEA Testing and Declarations

In response to global concerns regarding nitrosamine impurities, particularly NDMA (N-Nitrosodimethylamine) and NDEA (N-Nitrosodiethylamine), Taj Pharma has implemented a robust nitrosamine control strategy, fully aligned with EMA, US FDA, and CDSCO guidelines.

Vendor Declarations

  • All API vendors must submit Nitrosamine Risk Assessment Declarations, including:
    • Confirmation of absence or control of nitrosating agents
    • Synthetic route evaluation for nitrosamine formation risks
    • Residual amine precursors screening and control limits
    • Analytical testing data (as per USP <1469> or GC-MS/LC-MS validated methods)

In-House Analytical Verification

  • Our in-house QC laboratory performs independent nitrosamine testing using:
    • LC-MS/MS, GC-MS, and HRMS platforms
    • LOD/LOQ validation for NDMA and NDEA per ICH M7 guidelines
    • Use of certified reference standards (CRS) from EDQM/USP
    • Test frequency based on risk tier classification of each API

A Nitrosamine Compliance Certificate is issued and maintained for every API batch received, ensuring safety and regulatory compliance throughout the supply chain.


Lifecycle Maintenance & Regulatory Intelligence

Taj Pharma’s Regulatory Affairs team provides full DMF lifecycle support, including:

  • Tracking of DMF submission references and LOAs
  • Annual DMF updates and version control (as per 21 CFR §314.420)
  • Proactive review of supplier notifications on process changes, impurity revisions, or stability data
  • Real-time update of Module 3.2.S in response to API change controls
  • Coordination with health authority queries, deficiencies (IR, Day 120, Day 180 Q&A), and Variation/Amendment filings (Type IA/IB/II or Annual Notifications).

Our Regulatory Master Database (RMD) links each approved API with:

  • Current DMF status (open/closed)
  • CEP number and validity
  • Manufacturing site registration number
  • Nitrosamine assessment risk tier
  • Assigned QA and RA contacts

Ensuring API Compliance for Global Submissions

Taj Pharma’s commitment to technical compliance, regulatory completeness, and patient safety is reinforced by its meticulous approach to DMF collection, verification, and maintenance. Our qualified API sourcing model, coupled with analytical verification and lifecycle tracking, ensures that every drug product developed and manufactured at our OSD plant is supported by robust, agency-compliant API documentation, enhancing submission success and global market access.


BA/BE Studies & Clinical Trial Management

Taj Pharma’s Regulatory Affairs unit coordinates and supports:

  • Bioavailability (BA) and Bioequivalence (BE) Studies
  • Paper BE Reports for low-risk markets
  • BE Protocol Generation & Submission
  • Management of CRO partnerships for conducting GLP-compliant trials
  • Full clinical trial dossiers (ICH-GCP Compliant) for new drug applications

Our regulatory scientists monitor and evaluate studies from site selection to final report submission, ensuring clinical and ethical standards are upheld.

BA/BE Studies & Clinical Trial Management at Taj Pharma OSD Plant

The Regulatory Affairs Division at Taj Pharma’s Oral Solid Dosage (OSD) facility plays a pivotal role in the planning, execution, and regulatory oversight of Bioavailability (BA) and Bioequivalence (BE) studies. Our approach aligns with global regulatory frameworks, ensuring that all clinical and analytical operations are performed in accordance with ICH-GCP, GLP, WHO TRS 1003, and local regulatory guidelines such as CDSCO (India), EMA (Europe), US FDA, and GCC-DR.

We are strategically partnered with accredited CROs (Contract Research Organizations) for both clinical and bioanalytical phases, ensuring data integrity, reproducibility, and regulatory acceptance for global product registration across regulated and semi-regulated markets.


Bioavailability (BA) & Bioequivalence (BE) Study Planning and Execution

1. Regulatory-Compliant BE Centers

  • All BA/BE studies are conducted at CDSCO-approved BE centers, certified for GLP and GCP compliance, with multiple successful inspections by US FDA, WHO, EMA, ANVISA, and other agencies.
  • CROs are audited by Taj Pharma’s Quality Assurance team prior to study initiation to verify:
    • Ethics Committee Registration
    • Facility SOPs for clinical conduct
    • Data capture systems (e.g., electronic data capture – EDC platforms)
    • Bioanalytical method validations (LC-MS/MS systems)

2. Types of Studies Conducted

  • Single-dose, two-way crossover fasting/fed studies for immediate-release formulations
  • Steady-state multiple-dose BE studies for modified-release and chronic dosage forms
  • Replicate design studies for highly variable drugs (HVDs)
  • Pilot and pivotal studies for dossier submission in regulated markets
  • Waiver requests supported with in vitro dissolution data and BCS classification

Each study is designed to meet the target product profile (TPP) and product-specific bioequivalence criteria defined in the FDA product-specific guidances (PSGs) or EMA/WHO comparability frameworks.


Paper BE Reports for Low-Risk and Semi-Regulated Markets

For semi-regulated regions such as Africa, Southeast Asia, LATAM, and certain CIS countries, Taj Pharma supports the submission of Paper BE reports based on:

  • Previously published BE data with innovator comparison
  • Comparative dissolution profiles (CDP) using f2 similarity factor analysis
  • Waiver justification using BCS classification (Class I or III) supported by in-house permeability and solubility data
  • Bridging strategies involving biowaivers for strength proportionality

These reports include complete data packages such as formulation development rationale, batch manufacturing records, stability data, and analytical validation, which are often sufficient for national drug regulatory agencies in non-ICH countries.


BE Protocol Development and Submission

Before initiating any BA/BE study, Taj Pharma develops a scientifically sound, regulatory-aligned protocol that undergoes a rigorous review and approval process:

  • Design elements: Randomization, crossover model, washout period, number of subjects, safety monitoring, and sampling schedule
  • Comparator product verification: Innovator/Reference Listed Drug (RLD) matching (FDA/EMA/RxNorm database verified), expiry, and procurement documentation
  • Primary pharmacokinetic parameters: AUC0–t, AUC0–∞, Cmax, Tmax, T½, and Ka
  • Statistical methods: ANOVA-based analysis with 90% Confidence Intervals (CI) using log-transformed data for AUC and Cmax
  • Ethics Committee (EC) approval, subject informed consent, and safety monitoring plans

All protocols are structured in line with:

  • CDSCO Schedule Y guidelines
  • US FDA 21 CFR Part 320, 312
  • EMA Guideline on BE (CPMP/EWP/QWP/1401/98 Rev. 1)
  • WHO TRS 1003 Appendix 9

Strategic CRO Partnerships & Study Oversight

Taj Pharma’s Regulatory and Clinical Operations teams establish end-to-end coordination with GLP-compliant CROs, including:

  • Site qualification visits (SQVs)
  • Clinical site audits (pre, during, and post-study)
  • Vendor qualification assessments of both clinical and bioanalytical facilities
  • Use of validated bioanalytical methods with complete documentation of:
    • Linearity, accuracy, precision
    • LLOQ, ULOQ
    • Stability under various conditions
    • Matrix effect and recovery studies

All data is captured using electronic data capture (EDC) systems and exported into statistical analysis software such as WinNonlin® or SAS® for PK analysis.


Clinical Trial Dossier Preparation (ICH-GCP Compliant)

For new drug applications (NDAs) or value-added generics, Taj Pharma prepares full clinical trial dossiers including:

  • Module 5.3 – Clinical Study Reports
  • 5.3.1 – Bioequivalence Study Reports with:
    • Clinical and analytical reports
    • Individual subject data listings
    • Statistical analysis plans and outputs
    • Ethics Committee approvals
    • Certificate of analysis (COA) for test and reference products
  • Investigator Brochures
  • Pharmacokinetic and pharmacodynamic summaries
  • SAE (Serious Adverse Event) reporting
  • Medical monitoring reports and subject eligibility logs

We strictly adhere to ICH E6 (R2) GCP, Schedule Y, and Declaration of Helsinki principles for ethics and subject protection.


Monitoring & Quality Control of BA/BE Studies

Taj Pharma deploys dedicated regulatory scientists and clinical monitors (CRAs) who oversee:

  • Study feasibility and protocol review
  • On-site monitoring of clinical conduct, dosing, and sample collection
  • Inspection readiness of CRFs (Case Report Forms), subject compliance logs, and drug accountability
  • QC audits of bioanalytical raw data, chromatograms, and calibration curves
  • Review of final statistical outputs and conformance with pre-defined acceptance criteria (80–125% CI)

Each study is archived and retrievable for regulatory inspections, deficiency responses, and post-marketing surveillance (PMS) inquiries.


Clinical Data Integrity for Global Registration

Taj Pharma’s BA/BE and Clinical Research operations are built on a foundation of scientific rigor, regulatory insight, and ethical governance. Through strategic CRO alliances and internal QA oversight, we ensure that every study:

  • Meets global regulatory expectations
  • Supports dossier submissions for ANDAs, NDAs, and local registrations
  • Accelerates market access without compromising on data integrity or patient safety

Our clinical study management infrastructure reinforces Taj Pharma OSD Plant’s commitment to high-quality generics backed by robust clinical equivalence data.


Analytical Method Validation for Assay, Impurities & Solvents

We provide complete analytical method development and validation for:

  • Assay & Dissolution
  • Related Substances (Impurities)
  • Residual Solvents (as per ICH Q3C guidelines)

Each method is accompanied with HPLC chromatograms and UV spectrums, ensuring full traceability and reproducibility, validated under ICH Q2 (R1) guidelines.

Analytical Method Validation for Assay, Impurities & Residual Solvents at Taj Pharma OSD Facility

At Taj Pharma’s OSD Plant, analytical method development and validation form the backbone of our Quality Control (QC) and Regulatory Submission processes. We offer robust, reproducible, and scientifically sound analytical methods tailored to finished dosage forms (FDF), intermediates, and active pharmaceutical ingredients (APIs).

Our fully equipped QC and R&D laboratories perform method development and validation in strict accordance with ICH Q2(R1), ICH Q3A/B (Impurities), ICH Q3C (Residual Solvents), and ICH Q6A guidelines, ensuring global regulatory acceptability (US FDA, EMA, WHO PQ, TGA, GCC-DR, and others).


1. Analytical Method Development & Validation – Overview

Each analytical method undergoes a systematic development life cycle starting from feasibility trials to full validation. We validate the following core analytical parameters:

ParameterDescription
AssayDetermination of active ingredient content using HPLC/UV-spectrophotometry
DissolutionIn vitro release studies using USP/Ph. Eur. apparatus I or II
Related SubstancesIdentification and quantification of impurities and degradants via HPLC
Residual SolventsDetection and quantification of Class 1, 2, and 3 solvents via GC or HS-GC

Every method is optimized for:

  • Linearity, specificity, accuracy, precision, robustness
  • System suitability and solution stability
  • Compatibility with both QC release and stability testing under ICH Zone I–IVb

2. Assay & Dissolution Method Development

Assay by HPLC / UV

  • Assay methods are primarily performed using Reversed-Phase HPLC (RP-HPLC) systems with PDA detection, following USP/EP/JP monograph or in-house validated methods.
  • Validation parameters include:
    • Linearity: Minimum 5-point calibration curve with R² ≥ 0.999
    • Accuracy (Recovery Studies): 80%, 100%, 120% concentration levels
    • Precision: Repeatability (n=6) and intermediate precision (different analyst/instrument/day)
    • LOD/LOQ determined by signal-to-noise (S/N) ratio or calibration curve
  • Typical columns used: C18 (150 × 4.6 mm, 5 µm)
  • Mobile phase optimization to ensure peak symmetry, retention time consistency, and resolution

Dissolution Testing

  • Dissolution methods are developed using USP Apparatus I (Basket) or Apparatus II (Paddle).
  • Media selection based on:
    • API solubility and pKa
    • Biorelevant media (FaSSIF/FeSSIF) for BCS Class II/IV drugs
  • Sampling points: Typically 5, 10, 15, 30, 45, 60 minutes (based on formulation)
  • Quantification via UV-spectrophotometry or HPLC, with:
    • Filter validation
    • Sink condition verification
    • f1/f2 similarity factor analysis for comparative dissolution profiles

3. Related Substances (Impurities) Methodology

Impurity Profiling

  • Developed and validated using gradient HPLC methods, typically with PDA or UV detection; ELSD or MS used for non-chromophoric impurities.
  • Resolution criteria: Minimum R ≥ 2.0 between known impurities and API
  • Identification of:
    • Process-related impurities
    • Degradation products (acid/base hydrolysis, oxidative, photolytic, thermal)
  • Method validated for:
    • Specificity: No interference from placebo or excipients
    • Sensitivity: LOQ typically ≤ 0.05% (depending on specification)
    • Robustness: Flow rate, mobile phase pH, column temperature

Impurity Standards

  • Where impurity standards are not commercially available, they are synthesized in-house or qualified by:
    • Mass spectral characterization (LC-MS)
    • NMR (1H and 13C)
    • Elemental analysis
  • ICH Q3A/Q3B compliance: Total impurities ≤ specified thresholds for qualification and reporting

4. Residual Solvents – ICH Q3C Compliance

Testing by GC / Headspace-GC

  • Method development for Class 1, 2, and 3 solvents is performed using GC-FID or Headspace-GC with capillary columns such as DB-624, DB-1, or DB-WAX.
  • Class 1 (carcinogenic) solvents: Benzene, Carbon Tetrachloride
  • Class 2 (toxic) solvents: Methanol, Acetonitrile, Toluene, Methylene Chloride
  • Class 3 (low toxic potential) solvents: Ethanol, Acetone
  • Sample preparation includes:
    • Dimethyl Sulfoxide (DMSO) or N,N-Dimethylformamide (DMF) as diluents
    • Use of internal standards (IS) for accurate quantification
  • Method validated for:
    • LOD/LOQ against regulatory thresholds
    • Repeatability and intermediate precision
    • System suitability with RSD ≤ 15% for IS and known solvents

5. Documentation & Compliance

Each validated method is supported by complete Method Validation Protocol (MVP) and Method Validation Report (MVR), including:

  • Method development rationale and optimization pathway
  • Representative chromatograms, calibration curves, and UV-spectra
  • System suitability test (SST) criteria
  • Raw data and statistical analysis sheets
  • Analytical Method Transfer (AMT) protocols when required

Methods are designed to support:

  • Batch release (COA)
  • Stability studies (as per ICH Q1A(R2))
  • Dossier submissions (CTD Module 3.2.S/P.5.4)
  • Out-of-specification (OOS) investigations
  • Change control and post-approval variations

6. Compliance with Global Regulatory Authorities

Taj Pharma’s analytical methodologies are developed to withstand scrutiny from global regulatory agencies such as:

  • US FDA (21 CFR Part 211 & 58)
  • EMA/EDQM
  • Health Canada
  • TGA Australia
  • WHO PQ
  • MHRA UK
  • ANVISA Brazil

We have a centralized document management system (DMS) with controlled versioning and audit trails, ensuring traceability and inspection readiness.


Analytical Integrity as a Pillar of Quality

Through its state-of-the-art instrumentation, qualified analytical chemists, and rigorous validation protocols, Taj Pharma ensures that all analytical methods for assay, impurities, and residual solvents are scientifically justified, reproducible, and compliant with international guidelines.

This supports:

  • Regulatory filings (ANDA, MA, WHO PQ, ACTD/CTD)
  • Technology transfers
  • Market expansions
  • Audit readiness and continuous product quality assurance

Comparative Dissolution Profiles (CDP) Submission-Ready Reports

To support global ANDA and generic submissions, we offer:

  • CDP development using innovator comparison
  • Media selection, sink condition validation
  • Complete HPLC and UV profile reports
  • Multivariate statistical analysis

Reports include f2 similarity factor calculations, in line with FDA and EMA expectations, to facilitate product registration and substitution claims.

Comparative Dissolution Profiles (CDP) Submission-Ready Reports at Taj Pharma OSD Plant

At Taj Pharma, Comparative Dissolution Profile (CDP) generation is a critical pre-submission requirement and a standard component of regulatory documentation in support of global Abbreviated New Drug Applications (ANDAs), Marketing Authorization (MA) dossiers, and bio-waivers.

Our CDP studies are scientifically designed and executed under ICH, US FDA, EMA, TGA, and WHO PQ guidelines. We align each report with FDA’s Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, and EMA’s CPMP/EWP/QWP/1401/98 Rev. 1.


1. Objective of CDP Reports in Regulatory Submissions

Comparative Dissolution Profiles are used to:

  • Demonstrate pharmaceutical equivalence between test (generic) and reference (innovator) products
  • Support bio-waiver applications under BCS Class I and III
  • Provide in-vitro justification in cases where in vivo BE studies are not feasible
  • Aid in post-approval changes (scale-up, site transfer, formulation optimization)

2. CDP Study Design Framework at Taj Pharma

Each study is designed with statistical and scientific rigor, ensuring replicability and regulatory acceptance.

ParameterSpecification/Approach
Formulations ComparedTest product vs. Innovator/Reference Listed Drug (RLD)
Batch Numbers1 commercial scale batch of Test; 1–2 RLD batches (marketed samples)
Dosage StrengthHighest and/or multiple strengths for biowaiver justification
Dosage FormTablets / Capsules – immediate release (IR), modified release (MR), delayed release (DR)
Study ConditionsAs per USP/Ph. Eur. or developed in-house using validated methods

3. Dissolution Media Selection & Sink Condition Validation

Media selection is scientifically justified based on:

  • API solubility (pKa, LogP, BCS class)
  • Site of absorption
  • Innovator’s label claim
  • Biorelevant conditions

Typical media used:

  • 0.1N HCl
  • pH 4.5 Acetate buffer
  • pH 6.8 Phosphate buffer
  • Water

Each media is validated for sink conditions (volume should dissolve at least 3× the highest dose of drug) using:

  • Equilibrium solubility testing
  • Stability studies in dissolution media

4. Dissolution Method Parameters

  • Apparatus: USP Type II (Paddle) or Type I (Basket) based on dosage form
  • Volume: 900 mL ± 1% unless otherwise justified
  • RPM: 50 or 75, based on formulation type
  • Temperature: 37.0°C ± 0.5°C
  • Sampling Time Points: At least 4-6 time points, e.g., 5, 10, 15, 30, 45, 60 min

Each sampling point meets:

  • Triplicate measurement per unit (n=12 units)
  • Use of validated filters to avoid drug adsorption
  • Dissolution medium stability validation over test duration

5. Analytical Quantification – HPLC / UV Spectroscopy

All samples are analyzed using validated HPLC or UV methods:

  • Assay validation includes specificity, linearity, accuracy, and precision
  • HPLC with PDA detection is preferred for specificity in multi-component APIs
  • Calibration curves constructed with R² > 0.999
  • Use of internal standards where applicable

All chromatograms are:

  • Attached in the annexure of the report
  • Accompanied with integration data, SST, and blank controls

6. Data Analysis & Statistical Interpretation

Taj Pharma employs rigorous multivariate statistical tools to interpret CDP data.

Similarity Factor (f₂) Calculation

As per US FDA and EMA guidelines:

  • n = 12 units per batch
  • f₂ calculated as:
Analytical Method

Where:

  • RtR_tRt​ = % drug dissolved from reference at time t
  • TtT_tTt​ = % drug dissolved from test at time t

Acceptance Criteria:

  • f2f_2f2​ value between 50 and 100 indicates similarity
  • If f2<50f_2 < 50f2​<50, further in vivo studies or reformulation is required

Other statistical tools:

  • ANOVA with Dunnett’s test
  • Mahalanobis distance metric
  • Principal Component Analysis (PCA) (for global multivariate profile comparison)

7. Regulatory Report Formatting

Our CDP reports are prepared in submission-ready format compatible with:

  • CTD Module 3.2.P.5.6 – Justification of Specification
  • Module 5 (Clinical Study Reports – when used for biowaivers)
  • US FDA Biowaiver Justification (505(j))
  • EMA’s BCS-based biowaiver template
  • WHO PQP format for multisource generics

Each report includes:

  • Executive Summary
  • Test vs. Innovator tabular comparison
  • Method validation summary
  • Dissolution profiles graphs (mean ± SD)
  • f₂ calculation worksheets
  • Raw data appendices
  • Chromatograms and certificates of analysis

8. Quality Controls & Data Integrity

  • Data captured and stored via 21 CFR Part 11 compliant systems
  • Audit trails enabled on CDS and LIMS platforms
  • Reports undergo QA review before regulatory submission
  • Version-controlled under centralized DMS
  • Retained samples and backup data kept for minimum 5 years

9. Regulatory Acceptance & Experience

CDP reports developed at Taj Pharma have supported:

  • US FDA ANDA submissions (Para II–IV)
  • EMA DCP/MRP submissions
  • GCC, South Africa, Russia, ANVISA filings
  • WHO Prequalification applications

Many products have been granted biowaiver-based approvals using our comparative dissolution studies, reducing clinical burden and accelerating time to market.


CDP as a Pillar of Bioequivalence Strategy

Taj Pharma’s approach to CDP development ensures scientific robustness, regulatory compliance, and global acceptance. These reports play a crucial role in:

  • Generic substitution claims
  • Regulatory approvals without clinical BE
  • Justification of post-approval changes

Our Regulatory Affairs and R&D teams work collaboratively to generate submission-grade CDP reports, positioning Taj Pharma’s generic products for rapid global market entry.


Bioanalytical Validation, Protocol & Statistical Reports

Our regulatory documentation includes:

  • Bioanalytical protocols & method validation
  • Sample handling and processing
  • ANOVA and pharmacokinetic analysis for BE reports
  • Integration with CROs and laboratories for data traceability

Reports are structured in compliance with EMA, US FDA, and WHO formats to support successful dossier review.


SmPC & PIL Product Information Updates

We manage up-to-date and compliant product information documents, including:

  • Summary of Product Characteristics (SmPC)
  • Patient Information Leaflets (PIL)
  • Labelling Compliance Checklists
  • Updates based on post-marketing safety, quality reviews, and regulatory changes

All documents are translated and localized according to the linguistic and labeling norms of the respective country of submission.


Pharmacovigilance Systems: PSUR, RMP, PSMF

Taj Pharma has a robust pharmacovigilance support system. Our regulatory services include:

  • Preparation of PSURs (Periodic Safety Update Reports)
  • Development of Risk Management Plans (RMPs)
  • Maintenance of Pharmacovigilance System Master Files (PSMF)
  • Creation of SOPs for Safety Surveillance and Reporting

We work closely with QPPVs and Local PV Partners to ensure real-time adverse event monitoring and global compliance.


Document Legalization: Embassy Attestation & Apostille Services

Our Regulatory Affairs team assists in complete document legalization, including:

  • Notarization, Chamber of Commerce Attestation
  • Embassy Authentication
  • Apostille under The Hague Convention

Documents such as CPPs, GMP Certificates, COAs, COOs, and Product Registrations are processed efficiently with proper seals, signatures, and translations.


Global Regulatory Coverage

We serve a wide geographic landscape, delivering regulatory solutions for:

  • ASEAN (Indonesia, Vietnam, Philippines, Thailand, Malaysia, etc.)
  • CIS (Russia, Ukraine, Kazakhstan, Uzbekistan, etc.)
  • GCC (UAE, Saudi Arabia, Oman, Qatar, Bahrain, Kuwait)
  • AFRICA (Nigeria, Kenya, South Africa, Ethiopia, Egypt)
  • LATAM & ROW Markets (Colombia, Peru, Mexico, Chile)

Our end-to-end registration support ensures timely dossier approvals and long-term compliance for all products in our portfolio.


Why Choose Taj Pharma’s Regulatory Services?

  • Over 1000 Dossiers successfully filed across 40+ countries
  • Dedicated Regulatory Affairs, Pharmacovigilance, and Documentation teams
  • Integrated with formulation, QA/QC, analytical, and clinical departments
  • Fast turnaround for regulatory query responses and deficiency letters
  • End-to-end support from R&D to commercialization

Contact Taj Pharma Regulatory Affairs

For partnership, product registration, or dossier submission support, reach out to:

Taj Pharma India Ltd.
Plot No.1019, Vill. Sarigam, GIDC, Road No.10,
Dist. Valsad, Gujarat, India 396155
Phone: +91 84484 44095
WhatsApp: +91 7400009975 / 7400009976
Email: info@tajpharma.com
Website: www.tajpharmaindia.com